Aryl Hydrocarbon Receptor Market Report 2026

Aryl Hydrocarbon Receptor Market Overview

• Aryl Hydrocarbon Receptor market size has reached to $4.97 billion in 2025 • Expected to grow to $7.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5% • Growth Driver: Rising Incidence Of Autoimmune And Chronic Diseases Driving Market Growth Due To Increased Need For Targeted Therapeutic Pathways • Market Trend: Advancing Novel Modulators for Targeted Immune and Inflammatory Disease Therapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Aryl Hydrocarbon Receptor Market?

Aryl hydrocarbon receptor refers to a protein that binds environmental pollutants, such as dioxins, and regulates gene expression involved in immune and inflammatory responses. It is used for modulating various biological processes, including the treatment of autoimmune and inflammatory conditions like psoriasis, through selective activation or inhibition. The main types of aryl hydrocarbon receptors are CB-993113, CDR-914K058, cinnabarinic acid, and other types. CB-993113 is a small molecule inhibitor that targets the CBP/p300 bromodomain, being investigated for its potential in treating cancer and other diseases by modulating gene expression. These are distributed through various channels, including direct sales, online platforms, distributors, retail pharmacies, and wholesale suppliers. They find applications in treating conditions such as hepatocellular carcinoma, multiple sclerosis, obesity, and osteoporosis, among others. and are used by end-user industries such as pharmaceuticals, biotechnology, agriculture, environmental consultancy, and research institutions.

What Is The Aryl Hydrocarbon Receptor Market Growth Forecast?

The aryl hydrocarbon receptor market size is expected to see strong growth in the next few years. It will grow to $7.12 billion in 2030 at a compound annual growth rate (CAGR) of 7.5%. The growth in the forecast period can be attributed to growth in novel immunotherapies, expansion of precision medicine, rising investment in inflammation research, increasing clinical trials, growth in biotech startups. Major trends in the forecast period include growing research into immune modulation therapies, increasing development of selective ahr modulators, rising focus on autoimmune and inflammatory diseases, expansion of preclinical and early-stage trials, increased collaboration between pharma and biotech.

What Is The Driver Of The Aryl Hydrocarbon Receptor Market?

The rise in autoimmune diseases and chronic conditions is expected to propel the growth of the aryl hydrocarbon receptor market going forward. Autoimmune diseases and chronic conditions are long-term disorders where the immune system malfunctions or health issues persist. The rise in autoimmune diseases and chronic conditions is due to genetics, environment, lifestyle, gut imbalances, and better diagnostics. Aryl hydrocarbon receptor (AHR) agonists can modulate immune responses and inflammation, offering potential therapeutic benefits in autoimmune diseases and chronic conditions by regulating T-cell differentiation and immune cell function. For instance, in May 2023, according to the University of Oxford, a UK-based research university, autoimmune disorders affect about one in ten individuals, with 13% of women and 7% of men impacted across 19 studied autoimmune diseases. Therefore, the rise in autoimmune diseases and chronic conditions is driving the aryl hydrocarbon receptor (AHR) agonist market.

Key Players In The Global Aryl Hydrocarbon Receptor Market

Major companies operating in the aryl hydrocarbon receptor market are Bayer AG, Eli Lilly and Company, Organon & Co., Sigma-Aldrich Corporation, Bio-Techne Corporation, Abcam plc, R&D Systems Inc., Dermavant Sciences Inc., Cayman Chemical Company, Enzo Life Sciences Inc., Tocris Bioscience, Ikena Oncology Inc., MedChemExpress LLC, Hercules Pharmaceuticals BV, Active Biotech AB, AnTolRx Inc., Aqilion AB, Azora Therapeutics Australia Pty Ltd, Sol-Gel Technologies Ltd., Actavalon Inc.

Global Aryl Hydrocarbon Receptor Market Trends and Insights

Major companies operating in the Aryl Hydrocarbon Receptor (AhR) market are focusing on product innovation and formulation such as novel AhR modulators, to develop targeted therapies for immune-mediated and inflammatory diseases, improve safety profiles, and expand therapeutic options for patients with unmet medical needs. These modulators interact with the AhR pathway to regulate immune responses, offering potential for precision treatment in conditions like graft-versus-host disease, autoimmune disorders, and chronic inflammatory diseases. For instance, in May 2025, Equillium, a US-based biopharmaceutical company, announced its new EQ504 program, an Aryl Hydrocarbon Receptor modulator designed to target key immune pathways for enhanced anti-inflammatory activity. The EQ504 program is intended to offer improved selectivity and reduced off-target effects, enabling more effective modulation of immune responses while minimizing toxicity. This launch reflects the market trend toward precision immune modulation, where next-generation AhR-targeted therapies aim to address complex inflammatory pathways and provide novel solutions for patients who have limited treatment options.

What Are Latest Mergers And Acquisitions In The Aryl Hydrocarbon Receptor Market?

In September 2024, Organon & Co., a US-based pharmaceutical company, acquired Dermavant Sciences Ltd. for an approximate value of $1.2 billion. With this acquisition, Organon aims to strengthen its position in dermatology by integrating Dermavant's innovative dermatologic therapy, VTAMA (tapinarof) cream, 1%, into its portfolio. Dermavant Sciences Ltd. is a US-based company focused on developing innovative aryl hydrocarbon receptor (AHR) agonist-based therapies for dermatological conditions.

What Defines the Aryl Hydrocarbon Receptor Market?

The aryl hydrocarbon receptor market consists of sales of synthetic AHR agonists, natural AHR agonists, AHR-targeted enzyme inhibitors, and pharmaceuticals targeting AHR pathways. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Aryl Hydrocarbon Receptor Market Report 2026?

The aryl hydrocarbon receptor market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the aryl hydrocarbon receptor industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.